Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.
What happened
FDA inspected the Mount Laurel, New Jersey outsourcing facility (a compounder registered under section 503B to make sterile drugs without individual product approvals) from September 26 to October 25, 2023, and issued a Form FDA 483, the list of inspection observations, at the close. Investigators found that drug products meant to be sterile were made under conditions that could contaminate them, including skipped testing of the sterilizing agent for Fluorouracil PF, media fills and airflow (smoke) studies that did not include the riskiest production steps, and disinfectant dwell times shorter than the label requires. FDA also found that the company's quality unit did not investigate a detected trend of Mucor circinelloides mold in three ISO 8 cleanrooms between November 3, 2022 and July 10, 2023, and that lots of Tacrolimus ophthalmic suspension were made and distributed during that period anyway.
What FDA found
Drugs intended to be sterile were prepared, packed or held under insanitary conditions that could contaminate them.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The quality unit did not investigate a mold (Mucor circinelloides) trend found in cleanrooms C715, C711 and C735 over about eight months, and lots of Tacrolimus AQ exposed to those rooms were still produced and distributed.
21 CFR 211.192; 21 CFR 211.22(a)The company did not test the agent used to sterilize Fluorouracil PF, so it has no assurance the sterilization was complete.
21 CFR 211.113(b)Media fills, the test runs that show a facility can fill sterile product without contamination, did not include the highest-risk steps such as mixing drug components in large vessels.
21 CFR 211.113(b)The sporicidal disinfectant was given less contact time than its label requires, and the required dwell time was not always reached.
21 CFR 211.42(c)(10)(v)Labels did not give the quantity or proportion of each inactive ingredient, and containers did not carry MedWatch adverse event reporting information.
FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]
What FDA wants
FDA asks the company to write back within 15 working days describing the specific steps taken to fix each violation, with supporting documents, and to explain any delay if the work cannot be finished in that time. FDA also strongly recommends a full assessment of operations, especially aseptic processing, with a third-party consultant who has sterile manufacturing expertise.
Who should pay attention
- hospitals, surgery centers and clinics that buy compounded sterile drugs such as ophthalmic tacrolimus
- physicians and patients who receive compounded sterile injections or eye preparations
- distributors and pharmacies that resell or repackage 503B compounded drugs
This is a summary. Read the original letter on fda.gov.